ThreatBook Accredited by IMDA Singapore for Full Cycle Agentic Cybersecurity Solutions
The agentic security company is recognized for its innovation and high growth, and is endorsed to service government and large enterprise customers. Being accredited gives ThreatBook's customers peace of mind that its suite of security solutions is...
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 6, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics...
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases...
Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals Abstract honored with prestigious "Abstracts of...
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I...